Literature DB >> 32402293

Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge.

Barbara K Felber1, Zhongyan Lu2, Xintao Hu2, Antonio Valentin3, Margherita Rosati3, Christopher A L Remmel4, Joshua A Weiner4, Margaret C Carpenter4, Katelyn Faircloth4, Sherry Stanfield-Oakley5, Wilton B Williams6, Xiaoying Shen6, Georgia D Tomaras7, Celia C LaBranche8, David Montefiori8, Hung V Trinh9, Mangala Rao10, Munir S Alam6, Nathan A Vandergrift6, Kevin O Saunders8, Yunfei Wang6, Wes Rountree6, Jishnu Das11, Galit Alter11, Steven G Reed12, Pyone P Aye13, Faith Schiro13, Bapi Pahar13, Jason P Dufour13, Ronald S Veazey13, Preston A Marx14, David J Venzon15, George M Shaw16, Guido Ferrari5, Margaret E Ackerman4, Barton F Haynes17, George N Pavlakis18.   

Abstract

We compare immunogenicity and protective efficacy of an HIV vaccine comprised of env and gag DNA and Env (Envelope) proteins by co-administration of the vaccine components in the same muscles or by separate administration of DNA + protein in contralateral sites in female rhesus macaques. The 6-valent vaccine includes gp145 Env DNAs, representing six sequentially isolated Envs from the HIV-infected individual CH505, and matching GLA-SE-adjuvanted gp120 Env proteins. Interestingly, only macaques in the co-administration vaccine group are protected against SHIV CH505 acquisition after repeated low-dose intravaginal challenge and show 67% risk reduction per exposure. Macaques in the co-administration group develop higher Env-specific humoral and cellular immune responses. Non-neutralizing Env antibodies, ADCC, and antibodies binding to FcγRIIIa are associated with decreased transmission risk. These data suggest that simultaneous recognition, processing, and presentation of DNA + Env protein in the same draining lymph nodes play a critical role in the development of protective immunity. Published by Elsevier Inc.

Entities:  

Keywords:  ADCC; DNA; FcγR; HIV; Indian rhesus macaques; antibody; cellular immunity; humoral immunity; protein; vaccine

Mesh:

Substances:

Year:  2020        PMID: 32402293      PMCID: PMC7329227          DOI: 10.1016/j.celrep.2020.107624

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  89 in total

Review 1.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

2.  Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.

Authors:  Kevin O Saunders; Laurent K Verkoczy; Chuancang Jiang; Jinsong Zhang; Robert Parks; Haiyan Chen; Max Housman; Hilary Bouton-Verville; Xiaoying Shen; Ashley M Trama; Richard Scearce; Laura Sutherland; Sampa Santra; Amanda Newman; Amanda Eaton; Kai Xu; Ivelin S Georgiev; M Gordon Joyce; Georgia D Tomaras; Mattia Bonsignori; Steven G Reed; Andres Salazar; John R Mascola; M Anthony Moody; Derek W Cain; Mireille Centlivre; Sandra Zurawski; Gerard Zurawski; Harold P Erickson; Peter D Kwong; S Munir Alam; Yves Levy; David C Montefiori; Barton F Haynes
Journal:  Cell Rep       Date:  2017-12-26       Impact factor: 9.423

3.  Maximum diversity weighting for biomarkers with application in HIV-1 vaccine studies.

Authors:  Zonglin He; Youyi Fong
Journal:  Stat Med       Date:  2019-06-19       Impact factor: 2.373

4.  Bayesian hierarchical modeling for subject-level response classification in peptide microarray immunoassays.

Authors:  Gregory Imholte; Raphael Gottardo
Journal:  Biometrics       Date:  2016-04-08       Impact factor: 2.571

5.  Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development.

Authors:  Yunda Huang; Peter B Gilbert; David C Montefiori; Steve G Self
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

6.  Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Authors:  Dan H Barouch; Frank L Tomaka; Frank Wegmann; Daniel J Stieh; Galit Alter; Merlin L Robb; Nelson L Michael; Lauren Peter; Joseph P Nkolola; Erica N Borducchi; Abishek Chandrashekar; David Jetton; Kathryn E Stephenson; Wenjun Li; Bette Korber; Georgia D Tomaras; David C Montefiori; Glenda Gray; Nicole Frahm; M Juliana McElrath; Lindsey Baden; Jennifer Johnson; Julia Hutter; Edith Swann; Etienne Karita; Hannah Kibuuka; Juliet Mpendo; Nigel Garrett; Kathy Mngadi; Kundai Chinyenze; Frances Priddy; Erica Lazarus; Fatima Laher; Sorachai Nitayapan; Punnee Pitisuttithum; Stephan Bart; Thomas Campbell; Robert Feldman; Gregg Lucksinger; Caroline Borremans; Katleen Callewaert; Raphaele Roten; Jerald Sadoff; Lorenz Scheppler; Mo Weijtens; Karin Feddes-de Boer; Daniëlle van Manen; Jessica Vreugdenhil; Roland Zahn; Ludo Lavreys; Steven Nijs; Jeroen Tolboom; Jenny Hendriks; Zelda Euler; Maria G Pau; Hanneke Schuitemaker
Journal:  Lancet       Date:  2018-07-06       Impact factor: 79.321

7.  Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV.

Authors:  Jishnu Das; Srivamshi Pittala; Margaret E Ackerman; Thomas Broge; Caitlyn Linde; Todd J Suscovich; Eric P Brown; Todd Bradley; Harini Natarajan; Shu Lin; Jessica K Sassic; Sean O'Keefe; Nickita Mehta; Derrick Goodman; Magdalena Sips; Joshua A Weiner; Georgia D Tomaras; Barton F Haynes; Douglas A Lauffenburger; Chris Bailey-Kellogg; Mario Roederer; Galit Alter
Journal:  Nat Med       Date:  2018-09-03       Impact factor: 53.440

Review 8.  Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.

Authors:  Seleeke Flingai; Matias Czerwonko; Jonathan Goodman; Sagar B Kudchodkar; Kar Muthumani; David B Weiner
Journal:  Front Immunol       Date:  2013-11-04       Impact factor: 7.561

9.  Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.

Authors:  Ryan M Kramer; Michelle C Archer; Mark T Orr; Natasha Dubois Cauwelaert; Elyse A Beebe; Po-Wei D Huang; Quinton M Dowling; Alicia M Schwartz; Dawn M Fedor; Thomas S Vedvick; Christopher B Fox
Journal:  Int J Nanomedicine       Date:  2018-06-26

10.  Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection.

Authors:  Srivamshi Pittala; Kenneth Bagley; Jennifer A Schwartz; Eric P Brown; Joshua A Weiner; Ilia J Prado; Wenlei Zhang; Rong Xu; Ayuko Ota-Setlik; Ranajit Pal; Xiaoying Shen; Charles Beck; Guido Ferrari; George K Lewis; Celia C LaBranche; David C Montefiori; Georgia D Tomaras; Galit Alter; Mario Roederer; Timothy R Fouts; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  Mol Syst Biol       Date:  2019-05-02       Impact factor: 11.429

View more
  18 in total

1.  A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.

Authors:  Peng Zhang; Elisabeth Narayanan; Qingbo Liu; Yaroslav Tsybovsky; Kristin Boswell; Shilei Ding; Zonghui Hu; Dean Follmann; Yin Lin; Huiyi Miao; Hana Schmeisser; Denise Rogers; Samantha Falcone; Sayda M Elbashir; Vladimir Presnyak; Kapil Bahl; Madhu Prabhakaran; Xuejun Chen; Edward K Sarfo; David R Ambrozak; Rajeev Gautam; Malcom A Martin; Joanna Swerczek; Richard Herbert; Deborah Weiss; Johnathan Misamore; Giuseppe Ciaramella; Sunny Himansu; Guillaume Stewart-Jones; Adrian McDermott; Richard A Koup; John R Mascola; Andrés Finzi; Andrea Carfi; Anthony S Fauci; Paolo Lusso
Journal:  Nat Med       Date:  2021-12-09       Impact factor: 53.440

2.  Recent insights into Fc-mediated effector responses to HIV-1.

Authors:  Margaret C Carpenter; Margaret E Ackerman
Journal:  Curr Opin HIV AIDS       Date:  2020-09       Impact factor: 4.283

3.  New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure.

Authors:  Hui Li; Shuyi Wang; Fang-Hua Lee; Ryan S Roark; Alex I Murphy; Jessica Smith; Chengyan Zhao; Juliette Rando; Neha Chohan; Yu Ding; Eunlim Kim; Emily Lindemuth; Katharine J Bar; Ivona Pandrea; Cristian Apetrei; Brandon F Keele; Jeffrey D Lifson; Mark G Lewis; Thomas N Denny; Barton F Haynes; Beatrice H Hahn; George M Shaw
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

4.  Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs.

Authors:  Maria Blasi; Donatella Negri; Kevin O Saunders; Erich J Baker; Hannah Stadtler; Celia LaBranche; Benjamin Mildenberg; Georgeanna Morton; Andrew Ciarla; Xiaoying Shen; Yunfei Wang; Wes Rountree; Bala Balakumaran; Sampa Santra; Barton F Haynes; Anthony M Moody; Andrea Cara; Mary E Klotman
Journal:  NPJ Vaccines       Date:  2020-11-18       Impact factor: 7.344

5.  Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals.

Authors:  Savannah E Butler; Andrew R Crowley; Harini Natarajan; Shiwei Xu; Joshua A Weiner; Carly A Bobak; Daniel E Mattox; Jiwon Lee; Wendy Wieland-Alter; Ruth I Connor; Peter F Wright; Margaret E Ackerman
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

6.  Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques.

Authors:  Nichole R Klatt; Courtney Broedlow; Jessica M Osborn; Andrew T Gustin; Sandra Dross; Megan A O'Connor; Ernesto Coronado; Philip Barnette; Tiffany Hensley-McBain; Alexander S Zevin; Roshell Muir; Alexander Roederer; Solomon Wangari; Naoto Iwayama; Chul Y Ahrens; Jeremy Smedley; Cassandra Moats; Rebecca M Lynch; Elias K Haddad; Nancy L Haigwood; Deborah H Fuller; Jennifer A Manuzak
Journal:  NPJ Vaccines       Date:  2021-03-11       Impact factor: 7.344

7.  Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.

Authors:  Dieter Mielke; Sherry Stanfield-Oakley; Bhavesh Borate; Allan C deCamp; Guido Ferrari; Leigh H Fisher; Katelyn Faircloth; Marina Tuyishime; Kelli Greene; Hongmei Gao; Carolyn Williamson; Lynn Morris; Christina Ochsenbauer; Georgia Tomaras; Barton F Haynes; David Montefiori; Justin Pollara
Journal:  J Virol       Date:  2021-11-03       Impact factor: 6.549

8.  Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.

Authors:  Santhi Devasundaram; Margherita Rosati; Antonio Valentin; Svenja Weiss; Vincenza Itri; Hung V Trinh; Jenifer Bear; Bhabadeb Chowdhury; Celia C LaBranche; David Montefiori; Guido Ferrari; Mangala Rao; Xiang-Peng Kong; Susan Zolla-Pazner; George N Pavlakis; Barbara K Felber
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

9.  Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques.

Authors:  Pinyi Lu; Dylan J Guerin; Shu Lin; Sidhartha Chaudhury; Margaret E Ackerman; Diane L Bolton; Anders Wallqvist
Journal:  Front Immunol       Date:  2021-05-11       Impact factor: 7.561

10.  Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s.

Authors:  William D Tolbert; Dung N Nguyen; Marina Tuyishime; Andrew R Crowley; Yaozong Chen; Shalini Jha; Derrick Goodman; Valerie Bekker; Sarah V Mudrak; Anthony L DeVico; George K Lewis; James F Theis; Abraham Pinter; M Anthony Moody; David Easterhoff; Kevin Wiehe; Justin Pollara; Kevin O Saunders; Georgia D Tomaras; Margaret Ackerman; Guido Ferrari; Marzena Pazgier
Journal:  Front Immunol       Date:  2022-01-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.